Transforming Oncology Drug Development with Adaptive Trials

Complimentary Webinar

Thursday, April 7th at 11:00 AM Eastern Daylight Time

Please join us! Reserve your seat:

Register here >>>

Why should those engaged in oncology research be interested in adaptive trials?

Over 50% of confirmatory studies today end in failure – an especially distressing reality for oncologists and developers of cancer treatments.  But now, new adaptive study designs with a greater probability for successful outcome are helping reverse this discouraging trend.

The FDA’s 2010 Adaptive Trials Guidance document gives study sponsors confidence to utilize new study methods.  But how are adaptive designs changing oncology research today?

Join biostatistical pioneer Cyrus Mehta of Cytel and noted oncology advisor Dr. John Grous (our VP of Medical Affairs) for a live examination of the increase of adaptive oncology studies.

Using actual adaptive study examples, you will learn:

  • Definition and regulatory outlook – adaptations the FDA and EMA allow for both earlier and confirmatory stages
  • Who benefits and why? Impact on sponsor companies, their investors, medical community and trial patients
  • Oncology trial example – making the most of interim analysis: determining optimal adaptive changes with a “Promising Zone”
  • Harnessing “conditional power” to effectively de-risk oncology development
  • Ethical considerations: what do patients gain from participating in an adaptive study?

Who should register?

Anyone with a stake in oncology clinical R&D, including:

Oncology medical leadership, advisors, R&D management, clinical researchers, biostatisticians, consultants and the biopharmaceutical investment community.

We hope to see you!

Register here >>>